Cargando…

Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR

Since January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay. In this study, we evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudet, Agathe, Stephan, Robin, Bravo, Sophie, Sasso, Milène, Lavigne, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306735/
https://www.ncbi.nlm.nih.gov/pubmed/34359323
http://dx.doi.org/10.3390/diagnostics11071241
_version_ 1783727881901309952
author Boudet, Agathe
Stephan, Robin
Bravo, Sophie
Sasso, Milène
Lavigne, Jean-Philippe
author_facet Boudet, Agathe
Stephan, Robin
Bravo, Sophie
Sasso, Milène
Lavigne, Jean-Philippe
author_sort Boudet, Agathe
collection PubMed
description Since January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay. In this study, we evaluated one RT-PCR kit for this screening (ID SARS-CoV-2/UK/SA Variant Triplex(®), ID Solutions, Grabels, France) on 2207 nasopharyngeal samples that were positive for SARS-CoV-2. Using ID Solutions kit, 4.1% (92/2207) of samples were suspected to belonged to B.1.351 or P.1 variants. Next-generation sequencing that was performed on 67.4% (62/92) of these samples confirmed the presence of a B.1.351 variant in only 75.8% of the samples (47/62). Thirteen samples belonged to the UK variant (B.1.1.7), and two to A.27 with N501Y mutation. The thirteen with the UK variant presented one mutation in the S-gene, near the ΔH69/ΔV70 deletion (S71F or A67S), which impacted the detection of ΔH69/ΔV70 deletion. Using another screening kit (PKampVariantDetect SARS-CoV-2 RT-PCR combination 1 and 3(®) PerkinElmer, Waltham, MA, USA) on the misidentified samples, we observed that the two mutations, S71F or A67S, did not impact the detection of the UK variant. In conclusion, this study highlights the limitations of the screening strategy based on the detection of few mutations/deletions as well as it not being able to follow the virus evolution.
format Online
Article
Text
id pubmed-8306735
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83067352021-07-25 Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR Boudet, Agathe Stephan, Robin Bravo, Sophie Sasso, Milène Lavigne, Jean-Philippe Diagnostics (Basel) Article Since January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay. In this study, we evaluated one RT-PCR kit for this screening (ID SARS-CoV-2/UK/SA Variant Triplex(®), ID Solutions, Grabels, France) on 2207 nasopharyngeal samples that were positive for SARS-CoV-2. Using ID Solutions kit, 4.1% (92/2207) of samples were suspected to belonged to B.1.351 or P.1 variants. Next-generation sequencing that was performed on 67.4% (62/92) of these samples confirmed the presence of a B.1.351 variant in only 75.8% of the samples (47/62). Thirteen samples belonged to the UK variant (B.1.1.7), and two to A.27 with N501Y mutation. The thirteen with the UK variant presented one mutation in the S-gene, near the ΔH69/ΔV70 deletion (S71F or A67S), which impacted the detection of ΔH69/ΔV70 deletion. Using another screening kit (PKampVariantDetect SARS-CoV-2 RT-PCR combination 1 and 3(®) PerkinElmer, Waltham, MA, USA) on the misidentified samples, we observed that the two mutations, S71F or A67S, did not impact the detection of the UK variant. In conclusion, this study highlights the limitations of the screening strategy based on the detection of few mutations/deletions as well as it not being able to follow the virus evolution. MDPI 2021-07-12 /pmc/articles/PMC8306735/ /pubmed/34359323 http://dx.doi.org/10.3390/diagnostics11071241 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Boudet, Agathe
Stephan, Robin
Bravo, Sophie
Sasso, Milène
Lavigne, Jean-Philippe
Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR
title Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR
title_full Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR
title_fullStr Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR
title_full_unstemmed Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR
title_short Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR
title_sort limitation of screening of different variants of sars-cov-2 by rt-pcr
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306735/
https://www.ncbi.nlm.nih.gov/pubmed/34359323
http://dx.doi.org/10.3390/diagnostics11071241
work_keys_str_mv AT boudetagathe limitationofscreeningofdifferentvariantsofsarscov2byrtpcr
AT stephanrobin limitationofscreeningofdifferentvariantsofsarscov2byrtpcr
AT bravosophie limitationofscreeningofdifferentvariantsofsarscov2byrtpcr
AT sassomilene limitationofscreeningofdifferentvariantsofsarscov2byrtpcr
AT lavignejeanphilippe limitationofscreeningofdifferentvariantsofsarscov2byrtpcr